Reapplix has developed an innovative wound healing technology centered around the 3C Patch® System, which utilizes a small sample of the patient's own blood to create a personalized treatment for diabetic foot ulcers. This system effectively separates, coagulates, and compacts blood components into a solid patch that contains a concentration of proteins, active cells, and growth factors. The 3C Patch® is produced in approximately 20 minutes and is applied directly to the wound at the point of care. This evidence-based approach has been clinically proven to significantly accelerate the healing of hard-to-heal diabetic foot ulcers, making it a cost-effective solution that leverages the patient's unique biological healing capabilities.

The 3C Patch® has gained recognition from the International Working Group on the Diabetic Foot (IWGDF), which now recommends its use as an adjunctive treatment for enhancing the healing of diabetic foot ulcers. This endorsement underscores the clinical efficacy of the technology, which combines autologous leucocytes, platelets, and fibrin to promote wound healing. By focusing on personalized treatment, Reapplix aims to address the challenges faced by patients with chronic wounds, ultimately reducing the risk of severe complications such as amputation and lowering the overall costs associated with wound care.

Denmark

Founded in 2008, Reapplix specializes in the biological treatment and management of diabetic foot ulcers. Its innovative, patented 3C Patch® System draws on the individual patient’s capacity to heal and is clinically proven to accelerate wound healing of chronic diabetic foot ulcers. Headquartered in Denmark, with sales and distribution teams in the US and Europe, Reapplix won the Danish 2018 EY Entrepreneur of the Year Award in the life science category. Our business model is supported by high quality RCT evidence published in The Lancet in September 2018 and a 2019 IWGDF Recommendation.

Reapplix

Company Details